Cauldron Ferm Secures $13.25M, Eyes 60% Global Input Replacement
Tech News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Cauldron Ferm, a biotech startup with roots tracing back to the 1960s, has raised $19.75 million in a Series A funding round. Led by Main Sequence Ventures, the investment also includes Horizons Ventures, NGS Super, and SOSV. The companys technology, initially developed for growing protein from microbes, has evolved into a cost-effective, continuous fermentation process. Co-founder and CEO Michele Stansfield joined in 2012 and transformed the startup into a leader in synthetic biology. The funding will support Cauldron Ferms expansion into new biology-made products, aiming to replace 60% of global inputs.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/1bfeee5bc0b17a68